Cambodia surveillance for emerging infectious diseases
Ended Purchase Order Awarded Last action
- Contract number
- HT942523P0103
- Awardee
-
Chenda Polyclinic Company LIMITED UEI X37ZYFAFKMB5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,482,736
Award facts
- Opportunity
-
- procurement support, clinical and epidemiological services, purchase of supplies and equipment, transportation, communications and administrative support in Cambodia Pre-Solicitation · HT942523R0079 · Posted Mar 24, 2023
- Contract value 63% obligated
-
- $1,482,736.00 Current, with exercised options
- $2,361,447.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Cambodia
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $50,000 | |
| Exercise an Option | $372,408 | |
| Funding Only Action | $56,250 | |
| Exercise an Option | $477,078 | |
| Original award | $527,000 |
About this award
The Defense Health Agency awarded a $2.36 million firm fixed price purchase order to Chenda Polyclinic Company LIMITED on September 15, 2023, for surveillance support and clinical trials in Cambodia. The contract, which extends through September 18, 2028, supports the Armed Forces Research Institute of Medical Sciences (AFRMS) and the U.S. Army Medical Research Acquisition Activity in conducting emerging infectious disease surveillance and clinical research. The scope includes procurement support, clinical and epidemiological services, supplies and equipment purchases, transportation, communications, and administrative support across Cambodia and neighboring countries, with focus areas including respiratory viruses, leptospirosis, and malaria. The award includes services related to surveillance and clinical trials of anti-malarial drugs, vaccines, and anti-microbial and anti-viral therapeutics. No set-aside designation was applied to this requirement.
Performance will occur in Cambodia with work conducted by Chenda Polyclinic Company LIMITED's Kanyapak Reinvetch division. The contractor must provide office space, utilities, and security in compliance with U.S. Embassy regulations. This award follows a pre-solicitation sources sought notice posted in March 2023, which was issued for market research and planning purposes to identify potential vendors capable of supporting the Defense Health Agency's medical research initiatives in the region. The contract represents the Defense Health Agency's commitment to maintaining military medical research capabilities focused on infectious disease threats relevant to U.S. military personnel and regional biosecurity.
Quick answers
Who was awarded contract HT942523P0103?
HT942523P0103 was awarded to Chenda Polyclinic Company LIMITED by Defense Health Agency (Department of Defense) on September 15, 2023.
How much is contract HT942523P0103 worth?
The government has obligated $1,482,736 on HT942523P0103. Its potential value, with all options, is $2,361,447.
Was contract HT942523P0103 competed?
The extent of competition for HT942523P0103 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award